Galectin Therapeutics Inc. (GALT)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q1-2026 | 8-K (2026-05-15) · 99.1 | ||
| 10-KLatest | FY-2025 | 8-K (2026-03-31) · 99.1 | ||
| 10-Q | Q3-2025 | 8-K (2025-11-14) · 99.1 | ||
| 10-Q | Q2-2025 | 8-K (2025-08-14) · 99.1 | ||
| 10-Q | Q1-2025 | 8-K (2025-05-15) · 99.1 | ||
| 10-K | FY-2024 | 8-K (2025-03-31) · 99.1 | ||
| 10-Q | Q3-2024 | 8-K (2024-11-14) · 99.1 | ||
| 10-Q | Q2-2024 | 8-K (2024-08-13) · 99.1 | ||
| 10-Q | Q1-2024 | 8-K (2024-05-15) · 99.1 | ||
| 10-K | FY-2023 | 8-K (2024-03-29) · 99.1 | ||
| 10-Q | Q3-2023 | 8-K (2023-11-13) · 99.1 | ||
| 10-Q | Q2-2023 | 8-K (2023-08-14) · 99.1 |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Cover | ||
| Document and Entity Information | ||
| Audit Information | — |
|
| Statements | ||
| Consolidated Balance Sheets | ||
| Consolidated Balance Sheets (P) | ||
| Consolidated Statements of Operations | ||
| Consolidated Statements of Cash Flows | ||
| Condensed Consolidated Statements of Changes In Redeemable Convertible Preferred Stock and Stockholders' Deficit (unaudited) | — |
|
| Consolidated Statements of Changes In Redeemable Convertible Preferred Stock and Stockholders' Equity (deficit) | ||
| Notes | ||
| Accrued Expenses | — |
|
| Accrued Expenses and Other | — |
|
| Basis of Presentation and Liquidity | — |
|
| Basis of Presentation, Liquidity and Going Concern | — |
|
| Commitments and Contingencies | ||
| Common Stock | — |
|
| Common Stock Warrants | — |
|
| Convertible Line of Credit | ||
| Convertible Line of Credit Related Party and Supplemental Convertible Lines of Credit Related Party | — |
|
| Convertible Line of Credit Related Party and Supplemental Lines of Credit Related Party | — |
|
| Convertible Notes Payable | ||
| Convertible Notes Payable Related Party | ||
| Cybersecurity Risk Management and Strategy Disclosure | — |
|
| Fair Value of Financial Instruments | ||
| Galectin Sciences Llc | ||
| Income Taxes | — |
|
| Insider Trading Arrangements | ||
| Insider Trading Policies and Procedures | — |
|
| Leases | — |
|
| Loss Per Share | ||
| Nature of Business, Basis of Presentation and Liquidity | — |
|
| Nature of Business, Basis of Presentation, Liquidity, and Going Concern | — |
|
| Pay Vs Performance Disclosure | ||
| Property and Equipment | — |
|
| Segments | ||
| Stock-based Compensation | ||
| Stockholders' Equity | — |
|
| Subsequent Event | ||
| Summary of Significant Accounting Policies | — |
|
| Supplemental Convertible Lines of Credit | — |
|
| Warrants | — |
|